Our goal was to test the effects of insulin-like growth factor I (IGF-I) treatment on clinical deficits, lesion number and lesion size in acute demyelinating experimental autoimmune encephalomyelitis (EAE) induced in Lewis rats with an emulsion containing guinea pig spinal cord. In this EAE model, there is severe immune-mediated demyelination, which resembles that seen in actively demyelinating MS lesions. On day 12–13 after EAE induction, a total of 23 pairs of rats with the same mild degree of tail and hind limb weakness were given either intravenous IGF-I or placebo twice daily for 8 days. The daily IGF-I dose used in the first trial was 200 μg (about 0.6 mgkg-1) and in the second and third trials was 1 mg (about 3.0 mgkg-1). IGF-I treatment reduced permeability of the blood-spinal cord barrier to Evans blue-albumin. Maximum clinical deficit scores of IGF-I-treated rats were significantly lower and treated rats recovered faster than controls. IGF-I treatment produced significant reductions in weight loss and hind limb weakness. Treatment also improved treadmill walking, stride length and climbing performance. Morphometric analysis showed that spinal cord inflammatory lesions were significantly smaller and fewer in IGF-I-treated rots. The higher IGF-I dose produced a greater reduction in clinical and pathological deficits. We conclude that IGF-I treatment promotes clinical recovery by reducing EAE-induced blood-spinal cord barrier changes and the associated immune-mediated inflammatory lesions. Our results suggest that IGF-I may be useful in treating patients with multiple sclerosis and other demyelinating diseases.
2 Rutanen E-M, Pekonen F. (1990) Insulin-like growth factors and their binding proteins. Acta Endocrinol123: 7–13.
3.
3 Bondy CA. (1991) Transient IGF-I gene expression during the maturation offunctionally related central projection neurons. J Neurosci11: 3442–3455.
4.
4 Bondy CA, et al. (1992) Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience46: 909–923.
5.
5 Lee W-H, Javedan S, Bondy CA. (1992) Coordinate expression of insulin-like growth factor system compo nents by neurons and neuroglia during retinal and cerebellar development. J Neurosci12: 4737–4744.
7 Barres BA, et al. (1993) Multiple extracellular signals are required for long-term oligodendrocyte survival. Development118: 283–295.
8.
8 McMorris FA, Dubois-Dalcq M. (1988) Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat progenitor cells developing in vitro. J Neurosci Res21: 199–209.
9.
9 McMorris FA, et al. (1986) Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA83: 822–826.
10.
10 Mozell RL, McMorris FA. (1991) Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res30: 382–390.
11.
11 Carson MJ, et al. (1993) Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron10: 729–740.
12.
12 Mathews LS, et al. (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I*. Endocrinology123: 2827–2833.
13.
13 Beck KD, et al. (1995) Mice homozygous for disrupted insulin-like growth factor I gene display reduced myelination in the CNS and reduced numbers of hippocampal granule and striatal parvalbumin-containing neurons.Neuron (in press).
14.
14 Komoly S, et al. (1992) Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA89: 1894–1898.
15.
15 Liu X, et al. (1994) Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci5: 418–430.
16.
16 Yao D-L, et al. (1995) Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor-I (IGF-I) and IGF binding protein 2 (IGFBP-2) during myelin regeneration.J Neurosci Res, 40: 647–659.
17.
17 Raine CS. (1984) Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest50: 608–635.
18.
18 Raine CS. (1991) Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol17: 265–274.
19.
19 Somogyi P, Takagi H. (1982) A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocyto-chemistry. Neuroscience7: 1779–1783.
20.
20 Bondy C. (1994) Clinical uses of insulin-like growth factor-I. Ann Int Med120: 593–601.
21.
10 Kitz K, et al. (1984) Blood—brain barrier in chronic relapsing experimental allergic encephalomyelitis: a correlative study between cerebrospinal fluid protein concentrations and tracer leakage in the central nervous system. Acta Neuropathol63: 41–50.
22.
22 Oldstone MBA, Dixon FJ. (1968) Immunohistochemical study of allergic encephalomyelitis. Am J Pathol52: 251–263.
23.
23 Paterson PY, Koh CS, Kwaan HC. (1987) Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed Proc46: 91–96.
24.
24 Butter C, et al. (1991) Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomye litis in Biozzi AB/H mice. J Neurolog Sci104: 9–12.
25.
25 Bar RS, et al. (1988) Insulin, insulin-like growth factors and vascular endothelium. Am J Med85(Suppil. 5A): 59–70.
26.
26 Bar RS, et al. (1989) Insulin-like growth factor binding proteins from vascular endothelial cells: purification, characterization, and intrinsic biological activities. Endocrinology125: 1910–1920.
27.
27 Pardridge WM. (1993) Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann N Y Acad Sci692: 126–137.
28.
28 Rosenfeld RG, et al. (1987) Demonstration and structural comparison of receptors for insulin-like growth factor-I and-II (IGF-I and-II) in brain and blood-brain barrier. Biochem Biophys Res Commun149: 159–166.
29.
29 Grant MB, et al. (1993) Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor. Diabetologia36: 282–291.
30.
30 Lassmann H, Rossler K, Zimprich F, Vass K. (1991) Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier. Brain Pathol1: 115–123.
31.
31 Raine CS, Cannella B. (1992) Adhesion molecules and central nervous system inflammation. Sem Neurosci4: 207–211.
32.
32 Raine CS, et al. (1990) Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab Invest634: 476–489.
33.
33 Archelos JJ, et al. (1993) Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neural34: 145–154.
34.
34 Willenborg DO, et al. (1993) ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J Neuroimmunol45: 147–154.
36 Lindsey JW, Steinman L. (1993). Competitive PCR quantification of CD4, CDS, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis. J Neuroimmunol48: 227–234.
37.
37 Clark R, et al. (1993) Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest92: 540–548.
38.
38 Robbins K, et al. (1994) Immunological effects of insulin-like growth factor-I-enhancement of immunoglobulin synthesis. Clin Exp Immunol95: 337–342.
39.
39 Tapson VF, et al. (1988) Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest82: 950–957.
40.
40 Martin R, McFarland HF, McFarlin DE. (1992) Immunological aspects of demyelinating diseases. Anna Rev Immunol10: 153–187.
41.
41 Racke MK, et al. (1993) Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β2. J Neuroimmunol46: 175–184.
43 Vandenbark AA, Hashim G, offner H. (1993) TCR peptide therapy in autoimmune diseases. Intern Rev Immunol9: 251–276.
44.
44 Brück W, et al. (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol35: 65–73.
45.
45 McDonald WI. (1994) The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol53: 338–343.
46.
46 Ozawa K, et al. (1995) Patterns of oligodendroglia pathology in multiple sclerosis. Brain117: 1311–1322.
47.
47 Raine CS. (1994) The Dale E. McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion. Ann Neurol36 suppl.: S61–S72.
48.
48 Grinspan JB, et al. (1994) Protein growth factors as potential therapies for central nervous system demyeli-native disorders. Ann Neurol36 suppl.: S140–S142.
